Lit Matters #1: Treating Bacteremia: Lead with a β-lactam

Early antibiotic sequence appears to matter in bloodstream infection. In hospitalized patients with bacteremia receiving both vancomycin and a broad-spectrum beta-lactam, giving the beta-lactam first was associated with lower early mortality, reinforcing the practical rule to cover gram-negative pathogens up front.

Antibiotic Order in Bacteremia

• Sequence-of-therapy signal: In suspected bloodstream infection, the first antibiotic may influence survival; starting with a broad-spectrum beta-lactam was associated with lower 48-hour and 7-day mortality.
• Gram-negative first principle: Beta-lactams cover the organisms most likely to kill patients early in bacteremia, including many gram-negatives, while still covering most non-MRSA gram-positive pathogens.
• Common frontline beta-lactams: Piperacillin-tazobactam and cefepime accounted for most first-dose beta-lactam use, with meropenem used less often; we get into the practical implications in the episode.
• MRSA exception signal: When the bloodstream infection was MRSA, giving the beta-lactam before vancomycin did not show the same mortality benefit, a useful boundary on the main takeaway.
• Why the effect fits: The finding is biologically plausible: early beta-lactam therapy may better blunt gram-negative burden and could reduce endotoxin-related harm in pathogens such as E. coli.
• High-risk host relevance: This matters most in vulnerable patients like those with neutropenia, where gram-negative bacteremia is more common and early appropriate coverage is especially time-sensitive.